Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company
After Sigilon Therapeutics’ $126 million IPO last December, COO Devyn Smith started getting calls. Job offers, mostly, for this biotech or that, none that quite hit.
Then a recruiter reached out about an opening at a spinout from Feng Zhang’s MIT CRISPR lab that, despite a flashy launch, had gone largely quiet for three years. The company, Arbor Biotechnologies, was ready to enter a new phase and needed a new leader with experience bringing drugs into human trials. Smith, a former Pfizer executive remembering the press releases around Arbor’s launch, said yes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.